Trevi Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(10,902) | $(6,401) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 723 | 578 |
| Operating lease right-of-use assets | 120 | — |
| Depreciation and amortization | 35 | 19 |
| Accretion of available-for-sale marketable securities, net | (381) | (671) |
| Accretion/accrual of term loan discounts and debt issuance costs | — | 81 |
| Loss on disposal of property, equipment and leasehold improvements | — | 10 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 584 | (836) |
| Accounts payable | 294 | (914) |
| Accrued expenses and other liabilities | (940) | (63) |
| Net cash used in operating activities | (10,467) | (8,197) |
| Investing activities: | ||
| Proceeds from maturities of available-for-sale marketable securities | 22,173 | 18,000 |
| Purchases of available-for-sale marketable securities | (30,264) | (8,981) |
| Purchases of property, equipment and leasehold improvements | — | (57) |
| Net cash (used in) provided by investing activities | (8,091) | 8,962 |
| Financing activities: | ||
| Proceeds from exercises of stock options | 4 | 62 |
| Payments of finance lease | (32) | — |
| Repayments of term loan | — | (1,750) |
| Payments of offering costs | — | (15) |
| Net cash used in financing activities | (28) | (1,703) |
| Net decrease in cash and cash equivalents | (18,586) | (938) |
| Cash and cash equivalents at beginning of period | 32,397 | 12,589 |
| Cash and cash equivalents at end of period | $13,811 | $11,651 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.